Bone Biologics (BBLG) stock soars 80%, know the reason  

BBLG

On Monday, Bone Biologics Corp’sCorp’s stock price (BBLG) surged around 80 % after the market opened. Investors have gained more interest in the stock because of the H.C. Wainwright BioConnect Virtual Conference presentation.  

In a press release, Bone Biologics Corp. (BBLG) announced that the company company’s president and Chief Executive Officer, Jeffrey Frelick, will present at the H.C. Wainwright BioConnect Virtual Conference to be held in January.  

The investors took the news in a positive light, and the stock’s trade volume increased, bringing the stock price of BBLG to around 30% during the pre-market trade on Monday.   

At the time of writing, Bone Biologics Corp. (BBLG) stock was up 2.97 points (+86.59%), trading at $6.40. BBLG has a market capitalization of $65.726 million. The stock’s trading volume increased to 23,065,582 shares against the average trading volume of 564,473 shares.  

The conference will be held between January 10 to January 13, and a pre-recorded presentation will be available starting Monday, January 10 at 7:00 a.m.  

Bone Biologics Corporation is a developer of orthobiologic products for the spine fusion markets. A few days back, the company had announced that Jeffrey Frelick, the company’s president and CEO, would deliver a presentation at the H.C. Wainwright BioConnect Virtual Conference. Though the presentation will be pre-recorded, it brought the company into the spotlight, leaving more curious investors.   

As the conference starts today, the stock surge is a display of the potential of Bone Biologics (BBLG).   

About Bone Biologics Corp. (BBLG)

Bone Biologics Corp. (BBLG) was founded for pursuing regenerative medicine for bone. BBLG is undertaking some strategic partnerships to deliver groundbreaking results. The company is building on unprecedented research on the Nell-1 protein, and the research has produced a significant number of studies and publications. The company is currently focused on its development efforts for the bone graft substitute product on bone regeneration in spinal fusion. 

Related Posts